The RNA Cure?
It is being hailed as one of the biggest advances in biology in decades, one that could eventually lead to drugs for a wide range of diseases, from cancer to diabetes to AIDS. And one startup, Cambridge, MA-based Alnylam Pharmaceuticals, is in a particularly strong position to transform it into new pharmaceuticals.
In 1998, scientists discovered that RNA interference (RNAi)-a natural process in which small, double-stranded RNA molecules shut down the activity of particular genes-takes place in animals. For biomedical researchers, the implications were obvious; if you could selectively block genes involved in a disease, you could, in theory at least, stop it. Founded in 2002 by some of the pioneers of RNA interference research, Alnylam aims to synthesize small RNA molecules that could become the basis for a broad class of new drugs. So far, Alnylam has focused on cancer and metabolic diseases like diabetes. Its ambitious goal is to have a drug candidate in human testing by the end of 2005.
Keep Reading
Most Popular
Large language models can do jaw-dropping things. But nobody knows exactly why.
And that's a problem. Figuring it out is one of the biggest scientific puzzles of our time and a crucial step towards controlling more powerful future models.
The problem with plug-in hybrids? Their drivers.
Plug-in hybrids are often sold as a transition to EVs, but new data from Europe shows we’re still underestimating the emissions they produce.
Google DeepMind’s new generative model makes Super Mario–like games from scratch
Genie learns how to control games by watching hours and hours of video. It could help train next-gen robots too.
How scientists traced a mysterious covid case back to six toilets
When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.